Novaliq Receives FDA IND Clearance to Advance NOV05 in a Phase II Clinical Trial in Non-infectious Anterior Uveitis

Contributed by: Business Wire

Logo

Tags

Science

Biotechnology

Research

Pharmaceutical

Optical

Health

FDA

Clinical Trials

Novaliq

More Like This

Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease (Graphic: Business Wire)

Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease

Novaliq and Laboratoires Théa Announce Partnership and EU Approval for Vevizye® (Ciclosporin 0.1% Eye Drops Solution)

Heng Yi

Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease

PR Newswire associated0

NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months.

Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Associated with MGD

Five-year Pharmacovigilance study by NTC confirms safety of fixed-dose eye drops for Post-cataract Surgery